Please login to the form below

Not currently logged in
Email:
Password:

pembrolizumab

This page shows the latest pembrolizumab news and features for those working in and with pharma, biotech and healthcare.

NICE lung cancer backing for Keytruda is biggest expansion yet

NICE lung cancer backing for Keytruda is biggest expansion yet

NICE says Keytruda (pembrolizumab) “has the potential to be cost-effective, and was likely to extend life.” Patients whose tumours have EGFR or ALK mutations should be treated first with targeted

Latest news

More from news
Approximately 24 fully matching, plus 221 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics